ACHE and Alzheimer disease: Current first-line treatments for mild and moderate AD include the use of AChE inhibitors such as tacrine (IC50 = 0.424 μM in human AChE; h-AChE), galantamine (IC50 = 18.6 μM in h-AChE), and donepezil (IC50 = 0.023 μM in h-AChE) [14,15,16] (Figure 1), which consequently increases cholinergic tone in the mesocortical pathway [17,18].